Teva’s EpiPen Won’t Hit U.S. Market in Time for School Year, Report Says

Multi tool use
googletag.cmd.push(function() googletag.display('maavaron.ros.ctech');
googletag.pubads().addEventListener('slotRenderEnded', function(event)
if (event.slot.getSlotElementId() == 'maavaron.ros.ctech')
if (event.isEmpty)
document.getElementById('maavaron.ros.ctech').style.display = 'none';
);
);
try
if (maavaronshow==0)
console.log("maavaron hidden" + localStorage.maavaronView);
$('#siteOverlay').hide();
catch(err)
$('#siteOverlay').hide();
googletag.pubads().addEventListener('slotRenderEnded', function(event)
if (event.slot.getSlotElementId() == 'maavaron.ros.ctech')
if (event.isEmpty)
document.getElementById('maavaron.ros.ctech').style.display = 'none';
);
);
try
if (maavaronshow==0)
console.log("maavaron hidden" + localStorage.maavaronView);
$('#siteOverlay').hide();
catch(err)
$('#siteOverlay').hide();

- About
- Buzz
- Startups
- 24/7
Newsletter
googletag.cmd.push(function() googletag.display('prime.ctech'); );
Teva’s EpiPen Won’t Hit U.S. Market in Time for School Year, Report Says
The Israeli drugmaker received approval for a first generic version of Mylan’s auto-injector earlier this month
12:0226.08.18
Earlier this month, the U.S. Food and Drug Administration awarded Teva Pharmaceutical Industries Ltd. approval to market the first generic version of Mylan NV’s EpiPen auto-injectors. But now, amidst product shortages, SunTrust Robinson Humphrey analyst John Boris says Teva’s EpiPen—the price of which has yet to be announced—will not hit the market in time for the start of the school year.
For daily updates, subscribe to our newsletter by clicking here.
Cited in a Friday report by MarketWatch, Boris said that wholesalers expect at least two months of waiting before Teva’s generic version could be found on the shelves. In the U.S., the first day of school usually falls after Labor Day, on the first Monday of September, but some districts open in August. Deficiencies in the market could hinder both schools and parents looking to stock up.

googletag.cmd.push(function() googletag.display('ad.above.picture.article.ros.ctech'); );
Last week, Mylan announced extended expiration dates for some EpiPen batches in coordination with the FDA, to prepare for growing demand ahead of the school year. Mylan also stated it expects supply to stabilize in the fourth quarter of 2018.
jQuery(document).ready( function()
jQuery('.ArticlePromotionMor').click(function()
GA_report_local("Article_Promotion_Mor","Large",jQuery(this).attr('href'));
);
);
Related stories:
- Teva Wins FDA Approval for First Generic EpiPen
- Berkshire Hathaway Builds Teva Position for Third Quarter in a Row
- Teva's American Dream Boat is Sinking
googletag.cmd.push(function() googletag.display('more.artice.ros.ctech'); );
Teva was down 3.28% on NYSE on Friday market close.
googletag.cmd.push(function() googletag.display('strip.ros.ctech'); );
Cancel
Send
To all comments
Buzz

10 Israeli Startups that Are Looking For U.S. Investments






googletag.cmd.push(function() googletag.display('big.box1.ros.ctech'); );
Recently Read



googletag.cmd.push(function() googletag.display('sopranos.1.ros.ctech'); );
Recommended videos


googletag.cmd.push(function() googletag.display('big.box2.ros.ctech'); );
googletag.cmd.push(function() googletag.display('special.prime.ros.ctech'); );

- About
- Buzz
- Startups
- 24/7
Newsletter

- About
- Buzz
- Startups
- 24/7
Newsletter




|
@media all and (max-width: 1240px)
.TrajectoryTable width: 550px;
div.header-user-profile width: 890px;
.art-trajectory .TrajectoryTable width: 890px;overflow: hidden;margin-right: 57px;
$(document).ready(function()
if (navigator.appName == 'Microsoft Internet Explorer')
$('.trajectoryTextf').removeClass('OpenSansRegular');
);
function openWin(url,title,attrib) wref=window.open(url,title,attrib);if(MSIE_VER()>=5)wref.focus()
function openInnewWindow(url,width,height,toolbar)
if(toolbar==1)
openWin(url,'Calcalist','toolbar=yes,location=yes,directories=yes,status=yes,menubar=yes,scrollbars=yes,resizable=yes,width='+width+',height='+height)
else
openWin(url,'Calcalist','toolbar=no,location=no,directories=no,status=yes,menubar=no,scrollbars=no,movable=yes,resizable=yes,width='+width+',height='+height)
- Homepage
- News
googletag.cmd.push(function() googletag.display('prime.ctech'); );
googletag.cmd.push(function() googletag.display('prime.ctech'); );
googletag.cmd.push(function() googletag.display('prime.ctech'); );
Teva’s EpiPen Won’t Hit U.S. Market in Time for School Year, Report Says
The Israeli drugmaker received approval for a first generic version of Mylan’s auto-injector earlier this month
12:0226.08.18
Earlier this month, the U.S. Food and Drug Administration awarded Teva Pharmaceutical Industries Ltd. approval to market the first generic version of Mylan NV’s EpiPen auto-injectors. But now, amidst product shortages, SunTrust Robinson Humphrey analyst John Boris says Teva’s EpiPen—the price of which has yet to be announced—will not hit the market in time for the start of the school year.
For daily updates, subscribe to our newsletter by clicking here.
Cited in a Friday report by MarketWatch, Boris said that wholesalers expect at least two months of waiting before Teva’s generic version could be found on the shelves. In the U.S., the first day of school usually falls after Labor Day, on the first Monday of September, but some districts open in August. Deficiencies in the market could hinder both schools and parents looking to stock up.

googletag.cmd.push(function() googletag.display('ad.above.picture.article.ros.ctech'); );
Last week, Mylan announced extended expiration dates for some EpiPen batches in coordination with the FDA, to prepare for growing demand ahead of the school year. Mylan also stated it expects supply to stabilize in the fourth quarter of 2018.
jQuery(document).ready( function()
jQuery('.ArticlePromotionMor').click(function()
GA_report_local("Article_Promotion_Mor","Large",jQuery(this).attr('href'));
);
);
Related stories:
- Teva Wins FDA Approval for First Generic EpiPen
- Berkshire Hathaway Builds Teva Position for Third Quarter in a Row
- Teva's American Dream Boat is Sinking
googletag.cmd.push(function() googletag.display('more.artice.ros.ctech'); );
Teva was down 3.28% on NYSE on Friday market close.
googletag.cmd.push(function() googletag.display('strip.ros.ctech'); );
Cancel
Send
To all comments
Buzz

10 Israeli Startups that Are Looking For U.S. Investments






googletag.cmd.push(function() googletag.display('big.box1.ros.ctech'); );
Recently Read



googletag.cmd.push(function() googletag.display('sopranos.1.ros.ctech'); );
Recommended videos


googletag.cmd.push(function() googletag.display('big.box2.ros.ctech'); );
Teva’s EpiPen Won’t Hit U.S. Market in Time for School Year, Report Says
The Israeli drugmaker received approval for a first generic version of Mylan’s auto-injector earlier this month
12:0226.08.18
Earlier this month, the U.S. Food and Drug Administration awarded Teva Pharmaceutical Industries Ltd. approval to market the first generic version of Mylan NV’s EpiPen auto-injectors. But now, amidst product shortages, SunTrust Robinson Humphrey analyst John Boris says Teva’s EpiPen—the price of which has yet to be announced—will not hit the market in time for the start of the school year.
For daily updates, subscribe to our newsletter by clicking here.
Cited in a Friday report by MarketWatch, Boris said that wholesalers expect at least two months of waiting before Teva’s generic version could be found on the shelves. In the U.S., the first day of school usually falls after Labor Day, on the first Monday of September, but some districts open in August. Deficiencies in the market could hinder both schools and parents looking to stock up.

googletag.cmd.push(function() googletag.display('ad.above.picture.article.ros.ctech'); );
Last week, Mylan announced extended expiration dates for some EpiPen batches in coordination with the FDA, to prepare for growing demand ahead of the school year. Mylan also stated it expects supply to stabilize in the fourth quarter of 2018.
jQuery(document).ready( function()
jQuery('.ArticlePromotionMor').click(function()
GA_report_local("Article_Promotion_Mor","Large",jQuery(this).attr('href'));
);
);
Related stories:
- Teva Wins FDA Approval for First Generic EpiPen
- Berkshire Hathaway Builds Teva Position for Third Quarter in a Row
- Teva's American Dream Boat is Sinking
googletag.cmd.push(function() googletag.display('more.artice.ros.ctech'); );
Teva was down 3.28% on NYSE on Friday market close.
Teva’s EpiPen Won’t Hit U.S. Market in Time for School Year, Report Says
The Israeli drugmaker received approval for a first generic version of Mylan’s auto-injector earlier this month
12:0226.08.18
Earlier this month, the U.S. Food and Drug Administration awarded Teva Pharmaceutical Industries Ltd. approval to market the first generic version of Mylan NV’s EpiPen auto-injectors. But now, amidst product shortages, SunTrust Robinson Humphrey analyst John Boris says Teva’s EpiPen—the price of which has yet to be announced—will not hit the market in time for the start of the school year.
For daily updates, subscribe to our newsletter by clicking here.
Cited in a Friday report by MarketWatch, Boris said that wholesalers expect at least two months of waiting before Teva’s generic version could be found on the shelves. In the U.S., the first day of school usually falls after Labor Day, on the first Monday of September, but some districts open in August. Deficiencies in the market could hinder both schools and parents looking to stock up.

googletag.cmd.push(function() googletag.display('ad.above.picture.article.ros.ctech'); );
Last week, Mylan announced extended expiration dates for some EpiPen batches in coordination with the FDA, to prepare for growing demand ahead of the school year. Mylan also stated it expects supply to stabilize in the fourth quarter of 2018.
jQuery(document).ready( function()
jQuery('.ArticlePromotionMor').click(function()
GA_report_local("Article_Promotion_Mor","Large",jQuery(this).attr('href'));
);
);
Related stories:
- Teva Wins FDA Approval for First Generic EpiPen
- Berkshire Hathaway Builds Teva Position for Third Quarter in a Row
- Teva's American Dream Boat is Sinking
googletag.cmd.push(function() googletag.display('more.artice.ros.ctech'); );
Teva was down 3.28% on NYSE on Friday market close.
12:0226.08.18
Earlier this month, the U.S. Food and Drug Administration awarded Teva Pharmaceutical Industries Ltd. approval to market the first generic version of Mylan NV’s EpiPen auto-injectors. But now, amidst product shortages, SunTrust Robinson Humphrey analyst John Boris says Teva’s EpiPen—the price of which has yet to be announced—will not hit the market in time for the start of the school year.
For daily updates, subscribe to our newsletter by clicking here.
Cited in a Friday report by MarketWatch, Boris said that wholesalers expect at least two months of waiting before Teva’s generic version could be found on the shelves. In the U.S., the first day of school usually falls after Labor Day, on the first Monday of September, but some districts open in August. Deficiencies in the market could hinder both schools and parents looking to stock up.

googletag.cmd.push(function() googletag.display('ad.above.picture.article.ros.ctech'); );
Last week, Mylan announced extended expiration dates for some EpiPen batches in coordination with the FDA, to prepare for growing demand ahead of the school year. Mylan also stated it expects supply to stabilize in the fourth quarter of 2018.
jQuery(document).ready( function()
jQuery('.ArticlePromotionMor').click(function()
GA_report_local("Article_Promotion_Mor","Large",jQuery(this).attr('href'));
);
);
Related stories:
- Teva Wins FDA Approval for First Generic EpiPen
- Berkshire Hathaway Builds Teva Position for Third Quarter in a Row
- Teva's American Dream Boat is Sinking
googletag.cmd.push(function() googletag.display('more.artice.ros.ctech'); );
Teva was down 3.28% on NYSE on Friday market close.

googletag.cmd.push(function() googletag.display('ad.above.picture.article.ros.ctech'); );


googletag.cmd.push(function() googletag.display('ad.above.picture.article.ros.ctech'); );
googletag.cmd.push(function() googletag.display('ad.above.picture.article.ros.ctech'); );
jQuery(document).ready( function()
jQuery('.ArticlePromotionMor').click(function()
GA_report_local("Article_Promotion_Mor","Large",jQuery(this).attr('href'));
);
);
Related stories:
- Teva Wins FDA Approval for First Generic EpiPen
- Berkshire Hathaway Builds Teva Position for Third Quarter in a Row
- Teva's American Dream Boat is Sinking
googletag.cmd.push(function() googletag.display('more.artice.ros.ctech'); );
Related stories:
googletag.cmd.push(function() googletag.display('more.artice.ros.ctech'); );
googletag.cmd.push(function() googletag.display('strip.ros.ctech'); );
googletag.cmd.push(function() googletag.display('strip.ros.ctech'); );
Cancel
Send
To all comments
Cancel
Send
To all comments
Cancel
Send
To all comments
Cancel
Send
Cancel
Send
To all comments
To all comments
Buzz

10 Israeli Startups that Are Looking For U.S. Investments






Buzz

10 Israeli Startups that Are Looking For U.S. Investments






Buzz

10 Israeli Startups that Are Looking For U.S. Investments


10 Israeli Startups that Are Looking For U.S. Investments

10 Israeli Startups that Are Looking For U.S. Investments











googletag.cmd.push(function() googletag.display('big.box1.ros.ctech'); );
Recently Read



googletag.cmd.push(function() googletag.display('sopranos.1.ros.ctech'); );
Recommended videos


googletag.cmd.push(function() googletag.display('big.box2.ros.ctech'); );
googletag.cmd.push(function() googletag.display('big.box1.ros.ctech'); );
googletag.cmd.push(function() googletag.display('big.box1.ros.ctech'); );
Recently Read



Recently Read



Recently Read



googletag.cmd.push(function() googletag.display('sopranos.1.ros.ctech'); );
googletag.cmd.push(function() googletag.display('sopranos.1.ros.ctech'); );
Recommended videos


Recommended videos


Recommended videos


googletag.cmd.push(function() googletag.display('big.box2.ros.ctech'); );
googletag.cmd.push(function() googletag.display('big.box2.ros.ctech'); );
googletag.cmd.push(function() googletag.display('special.prime.ros.ctech'); );

Twitter
Facebook
Newsletter
Contact Us
Rss
About CTech
Terms of Use
Privacy Policy
About CTech
Terms of Use
Privacy Policy

